Content continues after advertisement

Research Note: Efficacy of a Nonnucleoside Inhibitor Against FIP Virus

Infectious Disease

March 2022

Sign in to Print/View PDF

Prevention and treatment options for FIP, a virulent pathotype of feline enteric coronavirus, are limited. Feline recombinant interferon omega is the most commonly available antiviral treatment, but its efficacy against FIP virus has not been well-demonstrated. ERDRP-0519 (ERDRP), a nonnucleoside inhibitor that targets RNA polymerase, is effective against in vitro and in vivo morbilliviruses. This study examined the in vitro efficacy of ERDRP against FIP virus. Results demonstrated significant inhibition of FIP virus replication in a dose-dependent manner, confirming ERDRP is highly effective against a coronavirus in vitro. Further study is needed to assess suitability of ERDRP in treatment of FIP virus in vivo.


For global readers, a calculator to convert laboratory values, dosages, and other measurements to SI units can be found here.

All Clinician's Brief content is reviewed for accuracy at the time of publication. Previously published content may not reflect recent developments in research and practice.

Material from Clinician's Brief may not be reproduced, distributed, or used in whole or in part without prior permission of Educational Concepts, LLC. For questions or inquiries please contact us.


Clinician's Brief:
The Podcast
Listen as host Alyssa Watson, DVM, talks with the authors of your favorite Clinician’s Brief articles. Dig deeper and explore the conversations behind the content here.
Clinician's Brief provides relevant diagnostic and treatment information for small animal practitioners. It has been ranked the #1 most essential publication by small animal veterinarians for 9 years.*

*2007-2017 PERQ and Essential Media Studies

© 2022 Educational Concepts, L.L.C. dba Brief Media ™ All Rights Reserved. Terms & Conditions | DMCA Copyright | Privacy Policy | Acceptable Use Policy